Jefferies Group LLC Madrigal Pharmaceuticals, Inc. Put Options Transaction History

Jefferies Group LLC

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2022 May 16, 2022	SELL	$55.89 - $101.89 $178,848 - $326,048	-3,200 Closed	0 $0
Q4 2021 Sep 21, 2023	BUY	$72.34 - $95.09 $231,488 - $304,288	3,200 New	3,200 $271,000
Q4 2021 Feb 14, 2022	SELL	$72.34 - $95.09 $130,212 - $171,162	-1,800 Reduced 36.0%	3,200 $271,000
Q1 2020 May 15, 2020	SELL	$66.76 - $93.49 $1.12 Million - $1.57 Million	-16,800 Reduced 77.06%	5,000 $334,000
Q4 2019 Feb 13, 2020	SELL	$84.28 - $118.5 $1.32 Million - $1.86 Million	-15,700 Reduced 41.87%	21,800 $1.99 Million
Q3 2019 Nov 13, 2019	SELL	$84.4 - $106.53 $2.15 Million - $2.72 Million	-25,500 Reduced 40.48%	37,500 $3.23 Million
Q2 2019 Aug 14, 2019	BUY	$91.13 - $142.5 $519,441 - $812,250	5,700 Added 9.95%	63,000 $6.6 Million
Q1 2019 May 15, 2019	BUY	$103.48 - $143.84 $1.38 Million - $1.91 Million	13,300 Added 30.23%	57,300 $7.18 Million
Q4 2018 Feb 14, 2019	BUY	$94.77 - $215.54 $2.84 Million - $6.47 Million	30,000 Added 214.29%	44,000 $4.96 Million
Q3 2018 Nov 14, 2018	BUY	$207.3 - $300.31 $2.9 Million - $4.2 Million	14,000 New	14,000 $3 Million

296

21.9M

819K

644K

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.52B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

Stay updated on Jefferies Group LLC with notifications on news.